Parkin L, et al. - Researchers determined the effect of introduction of long-acting muscarinic antagonist/long-acting beta agonist (LAMA/LABA) combination products on patterns of chronic obstructive pulmonary disease (COPD) therapy by using administrative healthcare data from Ontario, Canada. They found population-level changes in regimens used for COPD therapy following the introduction of LAMA/LABA combination products, however, no overall increase in long-acting therapy use was reported. Via different treatment pathways, transition of new users of LAMA/LABA and LAMA + LABA regimens to dual LAMA and LABA therapy was reported.